Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.